Movement Alert｜Alnylam Pharmaceuticals Rises 6.11% in Pre-Market Trading, Trading at $336.95

Market Focus

Jul 09

On July 9, Alnylam Pharmaceuticals rose 6.11% in pre-market trading, trading at $336.95/share, with Turnover of $153,700.

Within the Biotechnology sector where Alnylam Pharmaceuticals belongs, the overall sector performance was mixed. Among individual stocks, AbbVie up 0%, Vertex Pharmaceuticals up 0.39%, Gilead Sciences down 0.38%, Amgen down 0.48%, Regeneron Pharmaceuticals up 0%.

Alnylam Pharmaceuticals is a biopharmaceutical company focused on discovering, developing, and commercializing novel therapeutics based on RNA interference (RNAi) technology. Its marketed products include ONPATTRO and AMVUTTRA for hereditary transthyretin-mediated amyloidosis, GIVLAARI for acute hepatic porphyria, and OXLUMO for primary hyperoxaluria type 1, with multiple pipeline candidates in development addressing hypertension, Alzheimer's disease, and other conditions.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.gotigerhk.com/news/1151133185"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1151133185\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1151133185?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-07-09 16:03","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1151133185","market":"us","top_or_hot":-1,"title":"Movement Alert｜Alnylam Pharmaceuticals Rises 6.11% in Pre-Market Trading, Trading at $336.95","media":"Market Focus","content":"<p><p>On July 9, Alnylam Pharmaceuticals rose 6.11% in pre-market trading, trading at $336.95/share, with Turnover of $153,700.</p><p>Within the Biotechnology sector where Alnylam Pharmaceuticals belongs, the overall sector performance was mixed. Among individual stocks, AbbVie up 0%, Vertex Pharmaceuticals up 0.39%, Gilead Sciences down 0.38%, Amgen down 0.48%, Regeneron Pharmaceuticals up 0%.</p><p>Alnylam Pharmaceuticals is a biopharmaceutical company focused on discovering, developing, and commercializing novel therapeutics based on RNA interference (RNAi) technology. Its marketed products include ONPATTRO and AMVUTTRA for hereditary transthyretin-mediated amyloidosis, GIVLAARI for acute hepatic porphyria, and OXLUMO for primary hyperoxaluria type 1, with multiple pipeline candidates in development addressing hypertension, Alzheimer's disease, and other conditions.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Movement Alert｜Alnylam Pharmaceuticals Rises 6.11% in Pre-Market Trading, Trading at $336.95</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMovement Alert｜Alnylam Pharmaceuticals Rises 6.11% in Pre-Market Trading, Trading at $336.95\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1054767329\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Market Focus </p>\n<p class=\"h-time\">2026-07-09 16:03</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><p>On July 9, Alnylam Pharmaceuticals rose 6.11% in pre-market trading, trading at $336.95/share, with Turnover of $153,700.</p><p>Within the Biotechnology sector where Alnylam Pharmaceuticals belongs, the overall sector performance was mixed. Among individual stocks, AbbVie up 0%, Vertex Pharmaceuticals up 0.39%, Gilead Sciences down 0.38%, Amgen down 0.48%, Regeneron Pharmaceuticals up 0%.</p><p>Alnylam Pharmaceuticals is a biopharmaceutical company focused on discovering, developing, and commercializing novel therapeutics based on RNA interference (RNAi) technology. Its marketed products include ONPATTRO and AMVUTTRA for hereditary transthyretin-mediated amyloidosis, GIVLAARI for acute hepatic porphyria, and OXLUMO for primary hyperoxaluria type 1, with multiple pipeline candidates in development addressing hypertension, Alzheimer's disease, and other conditions.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"ALNY","symbol_name":"阿尔尼拉姆制药公司","start_time":0,"source_url":"","article_id":"1151133185","we_media_id":"1054767329","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1151133185","pubTimestamp":1783584233,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Market Focus","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1054767329","head_image":"https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a"},"summary":"On July 9, Alnylam Pharmaceuticals rose 6.11% in pre-market trading, trading at $336.95/share, with Turnover of $153,700.Within the Biotechnology sector where Alnylam Pharmaceuticals belongs, the...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"ALNY":"阿尔尼拉姆制药公司"},"translate_title":"走势提示|Alnylam Pharmaceuticals盘前涨6.11%，报336.95美元","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ALNY":1},"content_text":"On July 9, Alnylam Pharmaceuticals rose 6.11% in pre-market trading, trading at $336.95/share, with Turnover of $153,700.Within the Biotechnology sector where Alnylam Pharmaceuticals belongs, the overall sector performance was mixed. Among individual stocks, AbbVie up 0%, Vertex Pharmaceuticals up 0.39%, Gilead Sciences down 0.38%, Amgen down 0.48%, Regeneron Pharmaceuticals up 0%.Alnylam Pharmaceuticals is a biopharmaceutical company focused on discovering, developing, and commercializing novel therapeutics based on RNA interference (RNAi) technology. Its marketed products include ONPATTRO and AMVUTTRA for hereditary transthyretin-mediated amyloidosis, GIVLAARI for acute hepatic porphyria, and OXLUMO for primary hyperoxaluria type 1, with multiple pipeline candidates in development addressing hypertension, Alzheimer's disease, and other conditions.(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}